This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Terfenadine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Terfenadine is a non-sedative antihistamine.

Dosage in adults is 60 mg twice daily.

It has the potential to induce ventricular arrhythmias so it is essential to check the contraindications and to take a careful drug history.

Terfenadine should not be used if a patient has heart or liver problems; a patient should not take terfenadine with grapefruit juice; and the recommended dose should never be exceeded.

Terfenadine interacts with some other medications e.g. erythromycin and clarithromycin. Possible interactions with terfenadine should be checked before prescribing terfenadine.

Terfenadine is now only available on prescription.

The summary of product characteristics must be consulted before prescribing terfenadine.

Notes:

  • terfenadine is only available in the UK on a named-patient basis through specialist importers. There are no longer any licensed preparations containing terfenadine available in the UK (November 2005)

Reference:

  1. Committee on Safety of Medicines (21/4/1997). Terfenadine: proposed change to prescription use, letter from Professor M D Rawlins.
  2. Current Issues in Pharmacovigilance (1997), 23, 9.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.